Tetraphase Pharmaceuticals Inc. (TTPH) Trading Up 4.3%
Shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) shot up 4.3% during mid-day trading on Tuesday . The stock traded as high as $4.25 and last traded at $4.17, with a volume of 452,481 shares changing hands. The stock had previously closed at $4.00.
Several brokerages recently issued reports on TTPH. Wedbush reduced their price objective on shares of Tetraphase Pharmaceuticals from $8.00 to $4.00 and set an “outperform” rating on the stock in a report on Friday, May 13th. Gabelli lowered shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $7.00 price objective on the stock. in a report on Friday, May 13th. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, July 14th. Finally, Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Saturday, May 14th. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $14.85.
The company has a 50-day moving average price of $4.14 and a 200 day moving average price of $4.39. The company’s market capitalization is $150.83 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.01. The business earned $1.20 million during the quarter, compared to analysts’ expectations of $2.05 million. The company’s revenue was down 63.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.72) earnings per share. On average, analysts predict that Tetraphase Pharmaceuticals Inc. will post ($1.98) EPS for the current year.
An institutional investor recently raised its position in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System raised its position in Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 at the end of the most recent quarter.
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.